Drug Combination Details
| General Information of the Combination (ID: C64633) | |||||
|---|---|---|---|---|---|
| Name | Evodiamine NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CTNNB1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
| Experimental
Result(s) |
Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway. Mol Med Rep. 2015 Jan;11(1):257-62. | |||
